National Dementia Diagnostics Laboratory

The National Dementia Diagnostics Laboratory (NDDL)  is located at the Florey Institute of Neuroscience and Mental Health, in conjunction with the University of Melbourne.

The NDDL closes for Victorian and National Public Holidays. Please hold all diagnostic samples at -20 degrees celsius during affected periods. Contact us for further information about Specimen Reception at the NDDL. 

Cerebrospinal Fluid Alzheimer Disease Screen

Abeta1-42, Phospho-Tau

The Cerebrospinal Fluid (CSF) Alzheimer Disease Screen is an ante-mortem diagnostic test that detects alterations in the levels of biomarker proteins, specifically amyloid Abeta42 and phospho-tau, which are believed to be directly related to the pathophysiology of Alzheimer's disease (AD). Based on international experience, these CSF biomarkers and ratios offer approximately ~90% sensitivity and specificity for clinically overt AD and valuable prognostic information in persons with amnestic mild cognitive impairment (1). The recommendations detailed for CSF handling align with the consensus statement issued by the Alzheimer's Biomarker Standardisation Initiative (2,3) and the Test instruction by Roche.

NDDL is the NATA/ILAC accredited diagnostic laboratory in Australia that provides CSF diagnostic screening for Alzheimer’s disease (Abeta 1-42/phospho-tau proteins). 

The sample:

Diagnostic Testing Fees (no Medicare rebate)

AD screen (Amyloid1-42 and pTau) $300; any single protein $150; Total-Tau will only be tested in relation to Creutzfeldt Jakob disease.

The test is run weekly. Any sample received in the week before Monday will be included in the test. By pre-arrangement with NDDL for urgent sample, report can be issued within two days upon sample received with extra cost ($100 extra).


  1. Hansson et al. Alzheimer's & Dementia 2018; 14: 1470; Schindler et al. Alzheimer’s & Dementia 14 (2018) 1460.
  2. Hansson et al. Alzheimer’s & Dementia. 2018; 14: 1313-1333
  3. This laboratory is a member of the Alzheimer's Association QC program.

NDDL management

Prof. Steven Collins

Prof. Colin Masters

Contact/Courier details

Phone: (03) 9035 7243
Facsimile: (03) 9349 5105

Dr Qiao-Xin Li
National Dementia Diagnostics Laboratory
Florey Institute of Neuroscience and Mental Health
Kenneth Myer Building 
30 Royal Parade (corner of Genetics Lane)
Enter via Gate 11, rear loading dock
Parkville Victoria 3010

Cerebrospinal Fluid Creutzfeldt Jakob disease Screen

14-3-3 and Tau Protein Test

The 14-3-3 and tau proteins are non-specific, ante-mortem markers of central nervous system neuronal injury or death. Based on international experience in carefully selected patients, a positive result has approximately 80-90% sensitivity and specificity for sporadic Creutzfeldt-Jakob disease. While most often concordant, the two protein biomarkers should be viewed as complementary. False positives are recognized in various disease processes; for example encephalitis, encephalopathies and recent cerebral infarcts. Consequently, unselected sampling is less reliable as screening for a possible diagnosis of sporadic CJD. 

The NDDL/Australian National Creutzfeldt-Jakob disease Registry (ANCJDR) is the only NATA accredited diagnostic laboratory in Australia that provides 14-3-3 and Tau CSF protein testing.

For specific details regarding the specimen requirements and reception, please refer to the main ANCJDR website or contact the ANCJDR main office on Phone: 61 3 8344 1949 or Email:

Support us

Brain health affects all Australians.
You can support our research by making a donation or a bequest.


Latest breakthroughs, news, events & more.